Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes

What Was Tested

The paper reports a study of Orforglipron (Foundayo, non-peptide), published as a randomized controlled trial.

Orforglipron is a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist in clinical development for type 2 diabetes and weight management.

Who Took Part

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Orforglipron (Foundayo, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Orforglipron (Foundayo, non-peptide) study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Orforglipron (Foundayo, non-peptide) could be set against what happens without it.

The primary end point was the change from baseline to week 40 in the glycated hemoglobin level.

A key secondary end point was the percent change in body weight from baseline to week 40.

What Was Measured

PubMed files the paper under topics including Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Glycated Hemoglobin, Glycemic Control, Hypoglycemia, Oxadiazoles and Fluorine Compounds.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Orforglipron (Foundayo, non-peptide).

The abstract goes on to report its results in about 11 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (The New England journal of medicine), a journal based in United States.

More context: the Orforglipron (Foundayo, non-peptide) compound page, all human trials.